This November, Oncology Data Advisor is honoring Pancreatic Cancer Awareness Month and helping to raise awareness about early detection in hopes of improving outcomes for patients with this disease. In this interview, Oncology Data Advisor Editorial ...
In honor of Appendix Cancer Awareness Month this August, Dr. Thomas Abrams, Editor-in-Chief of Oncology Data Advisor and Assistant Professor of Medicine at Harvard Medical School, sat down to explain the different subtypes and presentations of append...
At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Oncology Data Advisor sat down with Allison Rosen, a colorectal cancer survivor, patient advocate, and Director of Project ECHO for the American Cancer Society. Ms. Rosen shares...
Oncology Data Advisor® · Pancreatic Cancer Awareness Month: Improving Early Detection With Joseph Kalis, PharmD, BCOP This November, Oncology Data Advisor is honoring Pancreatic Cancer Awareness Month and helping to raise awareness about e...
Oncology Data Advisor® · Appendix Cancer Awareness Month With Thomas Abrams, MD In honor of Appendix Cancer Awareness Month this August, Dr. Thomas Abrams, Editor-in-Chief of Oncology Data Advisor and Assistant Professor of Medicine at Har...
Oncology Data Advisor® · Spotlighting Zolbetuximab for Gastric/Gastroesophageal Junction Adenocarcinoma: Kohei Shitara, MD In this interview from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Kohei Shitara, a Me...
The FDA has approved pembrolizumab (Keytruda®, Merck) with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor 2 (HER2)–negative ...
The FDA has amended the existing indication of pembrolizumab (Keytruda®, Merck) with trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic human e...
The FDA has approved fruquintinib (Fruzaqla™, Takeda Pharmaceuticals, Inc.) for adult patients with metastatic colorectal cancer (mCRC) who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti–vascular endothelia...
